Kisspeptin Bolus Fails to Acutely Alter Vasopressin Levels in Healthy Humans
Background
Arginine-vasopressin (AVP) deficiency (AVP-D) is a condition caused by hypothalamic-pituitary damage to vasopressinergic neurons, leading to polyuria (excessive urination) and polydipsia (excessive thirst). Current diagnostic tests for AVP-D are often limited by low accuracy or poor tolerability. While kisspeptin (KP) has been shown to stimulate AVP release in animal models, no study has investigated KP as a provocative diagnostic test for AVP-D in humans.
Study Design
Results
Circulating AVP levels were consistently higher in males compared to females across all measured time points (p = .028), indicating a baseline sex difference. However, despite this, the primary finding was clear: An intravenous bolus of kisspeptin 112-121 did not acutely stimulate or significantly change circulating AVP levels in healthy adults at any time point post-administration. Specifically, no statistically significant increase or decrease in AVP was detected following the 0.24 nmol/kg kisspeptin dose over the 60-minute observation period. This indicates that, under the tested conditions, kisspeptin 112-121 did not elicit the expected AVP release observed in some animal models, leading to the conclusion that this specific IV kisspeptin bolus protocol is not supported as a provocative diagnostic test for AVP-D.
Why It Matters
This study provides crucial human data, indicating that an acute intravenous bolus of kisspeptin 112-121 at the tested dose is not effective as a provocative diagnostic test for AVP-D. This finding refines our understanding of kisspeptin's neuroendocrine role, highlighting potential species-specific differences in its interaction with the AVP system that may not translate directly from animal models. It suggests that while kisspeptin shows promise in animal models, its direct application for acute AVP stimulation in humans requires further investigation. Future research could explore alternative kisspeptin doses, different administration routes (e.g., sustained infusion), or novel kisspeptin analogues to identify protocols that might elicit an AVP response, potentially leading to improved diagnostic tools for AVP-D.